Magnesium Treatment in Hypoparathyroidism

Not Applicable

Completed

• Conditions: Hypoparathyroidism

• Registration Number: NCT00824226
• Lead Sponsor: University of Tartu

Brief Summary

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-01-15
• Study First Submitted QC: 2009-01-15
• Study First Posted: 2009-01-16
• Status Verified: 2011-08
• Primary Completion: 2011-08
• Study Completion: 2011-08
• Last Update Submitted: 2011-08-26
• Last Update Posted: 2011-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• primary or secondary hypoparathyroidism
• treatment with calcium plus vitamin D analogue
• ionized calcium 1,0-1,29 mmol/L
• magnesium level 0,7-1,05 mmol/L
• TSH 0.1- 10 imU/L

Exclusion Criteria

• any other disease known to influence plasma Ca level
• pregnancy
• creatinine > 150 microM/L
• patient has used supplementary magnesium within 2 previous months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Calcium level at the end of magnesium treatment compared to pretreatment level	3 weeks

Secondary Outcome Measures

Name	Time	Method
Calcium level after stopping treatment compared to the level at the end of magnesium treatment	2 weeks

Trial Locations

Locations (1)

Tartu University Hospital; 🇪🇪 Tartu, Estonia